28 October 2021

In memoriam: Boelien Geerts

Bianca-Olivia Nita

Bianca-Olivia Nita

Sadly, we received the news that Boelien Geerts, one of the first patient representatives of Oncode’s Patient Engagement Programme, passed away on October 14 from the effects of lung cancer.

Her absence will certainly be felt. We can openly say that Boelien was very active and committed to Oncode Institute’s efforts and mission. She contributed to our Patient Engagement Programme and inspired our researchers through her novel ideas, perspectives, and discussions based on her personal experiences and knowledge, and driven by a lot of enthusiasm. Since the onset of our Programme end of 2019, Boelien teamed up with Oncode Investigator Karin de Visser’s group at the NKI, from which she was in especially close contact with postdoctoral researcher Antoinette van Weverwijk.

She also gave valuable feedback on the recently awarded ZonMW research project of Oncode Investigator Peter ten Dijke and was to be part of its user board as a patient representative. Boelien was also an active member of Longfonds, a platform for patients with lung diseases.

We are grateful to Boelien for all her efforts. Her dedication, energy and positive attitude have inspired us and will remain in our hearts and minds. We wish her family and friends a lot of strength in this difficult time.

Other News

LOGO
Cancer Research UK forms strategic alliance with the Oncode Institute
Cancer Research UK, the world’s largest private funder of cancer research, today announces a strategic alliance with Oncode Institute. The five-year partnership is the first under Cancer Research UK’s new innovation organisation, Cancer Research Horizons, as well as being Oncode’s first UK partner. The alliance aims to foster innovation and collaboration between world-leading cancer researchers.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Georgi and david
A new critical regulator of interferon signaling discovered
The group of Oncode Investigator Daniel Peeper (NKI) has published in Nature Communications its discovery of a new regulator of interferon γ (IFNγ signaling. The IFNγ response pathway is associated with response to immunotherapy in cancer.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Sliertjes1
Simmunext: where immunotherapy and chemistry meet
Simmunext is a company name made of three words describing the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. The company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>